Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin.

Musashi-2 Silencing Exerts Potent Activity against Acute Myeloid Leukemia and Enhances Chemosensitivity to Daunorubicin.

RNA-binding protein Musashi-2 (Msi2) is known to play a critical role in leukemogenesis and contributes to poor clinical prognosis in acute myeloid leukemia (AML). However, the effect of Msi2 silencing on treatment for AML still remains poorly understood. In this study, we used lentivirus-mediated R...

Full description

Bibliographic Details
Main Authors:	Yixiang Han, Aifang Ye, Yan Zhang, Zhimin Cai, Wei Wang, Lan Sun, Songfu Jiang, Jianbo Wu, Kang Yu, Shenghui Zhang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2015-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4550418?pdf=render

Similar Items

MicroRNA-143 acts as a tumor suppressor through Musashi-2/DLL1/Notch1 and Musashi-2/Snail1/MMPs axes in acute myeloid leukemia
by: Fanfan Li, et al.
Published: (2023-05-01)

Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia
by: Kharas, Michael G., et al.
Published: (2012)

Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells
by: Yixiang Han, et al.
Published: (2018-09-01)

PD-L1 Is Expressed and Promotes the Expansion of Regulatory T Cells in Acute Myeloid Leukemia
by: Yuqing Dong, et al.
Published: (2020-07-01)

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia
by: Burnett, A, et al.
Published: (2016)

Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
by: Gerard Minuesa, et al.
Published: (2019-06-01)

Pretreatment platelet count predicts survival outcome of patients with de novo non-M3 acute myeloid leukemia
by: Qianying Zhang, et al.
Published: (2017-12-01)

Inhibition of EZH2 by chidamide exerts antileukemia activity and increases chemosensitivity through Smo/Gli-1 pathway in acute myeloid leukemia
by: Xuejie Jiang, et al.
Published: (2021-03-01)

Anti-CD123 antibody-modified niosomes for targeted delivery of daunorubicin against acute myeloid leukemia
by: Fu-rong Liu, et al.
Published: (2017-01-01)

A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia
by: Lin Zhang, et al.
Published: (2023-10-01)

Signaling pathways involved in chronic myeloid leukemia pathogenesis: the importance of targeting Musashi2-Numb signaling to eradicate leukemia stem cells
by: Foruzan Moradi, et al.
Published: (2019-06-01)

MiR-15a-5p Confers Chemoresistance in Acute Myeloid Leukemia by Inhibiting Autophagy Induced by Daunorubicin
by: Emeline Bollaert, et al.
Published: (2021-05-01)

Miyamoto Musashi
by: Pablo Pereda González
Published: (2012-07-01)

Miyamoto Musashi
by: Pablo Pereda González
Published: (2012-07-01)

Miyamoto Musashi
by: Pablo Pereda González
Published: (2012-07-01)

Randomized phase III trial comparing Daunorubicin and ara-C (DA) versus ara-C, Daunorubicin, and Etoposide (ADE) as induction chemotherapy in pediatric acute myeloid leukemia (InPOG-AML-16-01)
by: Venkatraman Radhakrishnan, et al.
Published: (2022-01-01)

Matrine induces apoptosis in human acute myeloid leukemia cells via the mitochondrial pathway and Akt inactivation.
by: Shenghui Zhang, et al.
Published: (2012-01-01)

Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways
by: Xiaolan Lian, et al.
Published: (2018-05-01)

Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy
by: Yi Zhang, et al.
Published: (2022-01-01)

Determination of caspase-3 activation fails to predict chemosensitivity in primary acute myeloid leukemia blasts
by: Strunk Timo, et al.
Published: (2005-06-01)

Correction to: Pin1 inhibition exerts potent activity against acute myeloid leukemia through blocking multiple cancer-driving pathways
by: Xiaolan Lian, et al.
Published: (2018-07-01)

Azelaic Acid Exerts Antileukemic Activity in Acute Myeloid Leukemia
by: Yunbao Pan, et al.
Published: (2017-06-01)

Self-Assembled Daunorubicin/Epigallocatechin Gallate Nanocomplex for Synergistic Reversal of Chemoresistance in Leukemia
by: Ki Hyun Bae, et al.
Published: (2022-12-01)

PB1848: IN VITRO CHEMOSENSITIVITY ASSAY PREDICTS TREATMENT RESPONSE IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
by: Yigeng Cao, et al.
Published: (2023-08-01)

Small Molecule Inhibitors of Microenvironmental Wnt/β-Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia
by: Paul Takam Kamga, et al.
Published: (2020-09-01)

Impact of Musashi-1 and Musashi-2 Double Knockdown on Notch Signaling and the Pathogenesis of Endometriosis
by: Theresa Strauß, et al.
Published: (2022-03-01)

DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway
by: Xuan Chu, et al.
Published: (2022-10-01)

MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models
by: Douglas D. Fang, et al.
Published: (2021-05-01)

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial
by: Xiaohui Suo, et al.
Published: (2023-05-01)

High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials.
by: Qiang Gong, et al.
Published: (2015-01-01)

Platelet Microparticles Protect Acute Myelogenous Leukemia Cells against Daunorubicin-Induced Apoptosis
by: Daniel Cacic, et al.
Published: (2021-04-01)

Casein-Based Nanoparticles: A Potential Tool for the Delivery of Daunorubicin in Acute Lymphocytic Leukemia
by: Nikolay Zahariev, et al.
Published: (2023-01-01)

Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities
by: Aude Le Roy, et al.
Published: (2018-05-01)

A review of the therapeutic role of the new third-generation TKI olverembatinib in chronic myeloid leukemia
by: Honglan Qian, et al.
Published: (2022-12-01)

Mechanism of RNA recognition by a Musashi RNA-binding protein
by: Jinan Wang, et al.
Published: (2022-01-01)

A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as potential risk factor.
by: Joanna M Lubieniecka, et al.
Published: (2013-11-01)

Binary Nanodrug-Delivery System Designed for Leukemia Therapy: Aptamer- and Transferrin-Codecorated Daunorubicin- and Luteolin-Coloaded Nanoparticles
by: Zhu Y, et al.
Published: (2023-01-01)

Surface-modified vacuole-based daunorubicin delivery system for acute myeloid leukaemia (AML) and their selective therapeutics
by: Wooil Choi, et al.
Published: (2022-12-01)

Silencing of XB130 is associated with both the prognosis and chemosensitivity of gastric cancer.
by: Min Shi, et al.
Published: (2012-01-01)

Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
by: Francesco Tarantini, et al.
Published: (2021-08-01)